Cell Therapy Technologies Companies

Q: What is the global market size of Cell Therapy Technologies Market?

Global Cell Therapy Technologies Market size was valued at USD 9.73 Billion in 2022 and is poised to grow from USD 2.12 Billion in 2023 to USD 55.32 Billion by 2031, growing at a CAGR of 12.14% in the forecast period (2024-2031)..

Cell Therapy Technologies Market Competitive Landscape

The competitive environment of the Global Cell Therapy Technologies Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Emerging biotechnology companies and start-up companies are leveraging technological innovation and collaborative research to gain competitive advantage and participate in the development of new cell therapies loudly. Partnerships, licensing agreements, and acquisitions are common strategies among market players to expand their capabilities, acquire complementary technologies, and strengthen their market positions.

Top Player’s Company Profiles

Thermo Fisher Scientific Inc.

GE Healthcare

Lonza Group

Merck KGaA (MilliporeSigma)

Terumo BCT (Terumo Corporation)

STEMCELL Technologies Inc.

Sartorius AG

Therakos Inc. (Mallinckrodt Pharmaceuticals)

Miltenyi Biotec

Fresenius Kabi AG

Pluristem Therapeutics Inc.

MaxCyte Inc.

CellGenix GmbH

Novartis International AG

Gilead Sciences Inc.

FAQs

Cell Therapy Technologies Market size was valued at USD 9.73 Billion in 2022 and is poised to grow from USD 2.12 Billion in 2023 to USD 55.32 Billion by 2031, growing at a CAGR of 12.14% in the forecast period (2024-2031).

The competitive environment of the Cell Therapy Technologies Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Emerging biotechnology companies and start-up companies are leveraging technological innovation and collaborative research to gain competitive advantage and participate in the development of new cell therapies loudly. Partnerships, licensing agreements, and acquisitions are common strategies among market players to expand their capabilities, acquire complementary technologies, and strengthen their market positions. 'Thermo Fisher Scientific Inc.', 'GE Healthcare', 'Lonza Group', 'Merck KGaA (MilliporeSigma)', 'Terumo BCT (Terumo Corporation)', 'STEMCELL Technologies Inc.', 'Sartorius AG', 'Therakos Inc. (Mallinckrodt Pharmaceuticals)', 'Miltenyi Biotec', 'Fresenius Kabi AG', 'Pluristem Therapeutics Inc.', 'MaxCyte Inc.', 'CellGenix GmbH', 'Novartis International AG', 'Gilead Sciences Inc.'

The market growth is also supported by the constant introduction of new technologies to enable cutting-edge therapies. The introduction of proprietary cells is generally considered to be the most efficient way to obtain a large population of targets for a single product. For example, Immunicum is using Chimeric Antigen Receptor T cell (CAR-T) growth, dendritic cell neoantigen presentation technology, and T-cell primers to improve its immuno-oncology product development.

The demand for advanced cell therapy technology is increasing as advanced analytical tools are used for quality control and quality improvement. Combining new diagnostics, imaging technologies and data analytics makes it easy to monitor and characterize cellular materials to ensure efficacy and increased safety profiles. If the focus is on developing new biomaterials and scaffolds to enhance cell delivery and engraftment increases the interest in cell therapy technologies. These properties provide improved biocompatibility, controlled release kinetics, and better retention at the target site, further enhancing the therapeutic potential of cell-based therapies in regulatory development and collaboration involvement and increased collaboration between research institutions supports innovation and accelerates the translation of cell therapy technologies from bench to bedside.

North America accounted for the largest revenue share of 58.7% in 2023. This is due to collaboration between research institutes and major pharmaceutical companies. Growth is coming through several joint ventures in this area. For example, in June 2022, Ematics partnered with Bristol Myers Squibb to develop the Gamma Delta Allogenic Cell Therapy Programs. The United States is a leading player in the cell therapy technology market. It emphasizes the research, development, and development of cell therapies, particularly in cancer, cardiology, and neuroscience in the US. The regulatory environment is supportive of new cell therapies, and the country has a variety of services and research institutes.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Cell Therapy Technologies Market Competitive Landscape

Cell Therapy Technologies Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Cell Therapy Technologies Market Competitive Landscape

Cell Therapy Technologies Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Cell Therapy Technologies Market?

Who are the key vendors in the Cell Therapy Technologies Market?

What is the key driver of Cell Therapy Technologies Market?

What is the key market trend for Cell Therapy Technologies Market?

Which region accounted for the largest share in Cell Therapy Technologies Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300